Enhance.MD’s current menu makes the difference between an introductory price and an ongoing rate visible. Its GLP-1 Core semaglutide offer starts at $49 for the first month and lists $212 per month afterward. That is a more useful financial record than quoting $49 as the normal recurring price.
The page also names several other compounded offerings, including tirzepatide and a semaglutide-plus-tirzepatide combination. These are distinct advertised preparations. This review describes their commercial and evidence boundaries without endorsing a combination or suggesting an individual treatment choice.
The first month is not the continuing amount
The GLP-1 Core panel pairs $49 initially with $212 afterward. GLP-1 Advanced tirzepatide has a separate $99 first-month and $280 continuing display. The price comparison should keep each medicine and stage together rather than mixing the lowest initial figure with another treatment’s features. Publishing the later rate makes the introductory offer clearer, even though the complete selected financial agreement is still needed.
The panels describe medication, ongoing provider care and periodic metabolic laboratory testing among the features. These are advertised inclusions. A complete selected agreement would still clarify the billing interval, renewal and any additional services. The cost guide follows that distinction.
The combination is a different preparation
GLP-1 Elite is advertised as semaglutide plus tirzepatide, with its own initial and continuing rates. The page describes a rationale about receptor pathways and greater benefit. That is the brand’s marketing explanation, not a controlled comparison establishing the current combined product’s clinical superiority.
The exact named preparation needs its own evidence. Approval or trials for a separately manufactured branded medicine cannot simply be extended to a compounded combination. The treatment guide explains the approval boundary without providing a protocol for any of these products.
The professional review remains conditional
The disclosure says prescription products require consultation with a healthcare professional who determines whether prescribing is appropriate. It also explicitly states that the compounded medication is not FDA-approved and that its safety or effectiveness has not been verified by FDA.
The product imagery is marked as marketing rather than the actual vial. That makes the dispensing label another necessary record, not something the illustration authenticates. This review has not completed an intake or established that a particular advertised preparation is available or appropriate for the reader.
A useful quote preserves both time and identity
Enhance.MD’s visible continuing amounts make its introductory offers more interpretable. The unresolved questions concern the complete selected terms and evidence for the exact formula. A low entry rate and a broad metabolism claim answer different questions and should not be used to strengthen each other.
The SnagRx review follows a flat-pricing claim, while Trimi separates an annual equivalent from upfront payment. The renewal guide makes those models comparable without declaring any advertised preparation a clinical winner.
Compare another model
SnagRx · BetterMe Rx · Wegovy · Zepbound
The invoice guide and product-status guide explain the distinctions behind these entries.
Documents used
Official public information reviewed October 1, 2026. Advertising describes an offer; it is not independent verification of treatment outcomes.